TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Sta... ( FRAZER Pa. Dec. 3 /- Cephalon Inc...)

TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA

Date:12/3/2007

FRAZER, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review designation to the TREANDA(R) (bendamustine HCl) New Drug Application (NDA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). CLL is a slowly progressing blood and bone marrow disease with an estimated 15,000 new cases diagnosed every year in the United States. Cephalon filed the TREANDA NDA for CLL in September 2007 and the FDA will make a review decision by the end of March 2008.

"If approved, TREANDA will make a meaningful difference as the first new CLL treatment option approved by the FDA since 2001 and could be available as soon as the second quarter of 2008," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations.

The FDA assigns priority review to drugs that, if approved, would offer major advances in treatment or would provide treatment to patients where no adequate therapy exists. Priority review reduces the targeted NDA review time from 10 months to six months. FDA granted orphan drug status for TREANDA for CLL in August 2007, which would entitle Cephalon to a seven-year period of marketing exclusivity in the United States, if the product is approved for this indication.

About TREANDA

TREANDA is a rationally designed purine analog/alkylator hybrid. Preclinical data demonstrate that this rationally designed hybrid acts in two ways to kill cancer cells. TREANDA damages the DNA in cancer cells, which leads to the normal path of cell death (apoptosis). It also stops cancer cells from dividing to create new cancer cells. This dual-action of TREANDA may be attributable to its unique chemical design.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Pharma GmbH. Bendamustine HCl, the active ingredient in
'/>"/>

3

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
4. PreMD Provides Update on 510(k) Application for PREVU(x) POC
5. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. PartsSource Awarded US Patent for PartsFinder(TM) Application
9. HealthCentral.com Launches Greeting Card Application on Facebook.com
10. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
11. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125

Post Your Comments:

TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Sta...( FRAZER Pa. Dec. 3 /- Cephalon Inc...),Health